PMID- 23742947
OWN - NLM
STAT- MEDLINE
DCOM- 20150724
LR  - 20141202
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 21
IP  - 1
DP  - 2015 Jan
TI  - Impact of anticoagulation on coronary flow in patients with non-ST elevation 
      acute coronary syndrome.
PG  - 48-57
LID - 10.1177/1076029613490826 [doi]
AB  - The effect of anticoagulation by heparin on patients with non-ST elevation acute 
      coronary syndrome (NSTE-ACS), receiving early dual antiplatelet therapy, has not 
      been fully evaluated. We classified 355 patients with NSTE-ACS according to the 
      adequacy of anticoagulation (percentage of low activated partial thromboplastin 
      time [APTT] level). The 6-hour APTT level was optimal in only 23.1% of the 
      patients treated with unfractionated heparin. The rate of poor preprocedural 
      coronary blood flow (thrombolysis in myocardial infarction grade <3, 39.1%, 
      30.5%, 30.3%, and 33.9% in the 100% low-, 99% approximately 50% low-, 49% approximately 1% low-, and 0% 
      low-APTT group, respectively, P = .632) and bleeding events did not differ 
      between the groups. Instead, in multivariate analysis, the diagnosis of 
      myocardial infarction was the only independent predictor of poor coronary flow. 
      For bleeding events, the usage of glycoprotein IIb/IIIa inhibitor appeared to be 
      a sole risk factor. In conclusion, inadequate preprocedural anticoagulation was 
      not associated with adverse outcomes in patients with NSTE-ACS treated with dual 
      antiplatelet agents.
CI  - (c) The Author(s) 2012.
FAU - Kang, Jeehoon
AU  - Kang J
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea Department of Internal Medicine, Seoul National University 
      Hospital, Seoul, South Korea.
FAU - Cho, Young-Seok
AU  - Cho YS
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea flammeus1@gmail.com.
FAU - Song, Hee Yun
AU  - Song HY
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Kim, Hyun Jin
AU  - Kim HJ
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea Department of Internal Medicine, Seoul National University 
      Hospital, Seoul, South Korea.
FAU - Oh, Il-Young
AU  - Oh IY
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Yoon, Chang-Hwan
AU  - Yoon CH
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Suh, Jung-Won
AU  - Suh JW
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Kim, Kwang-Il
AU  - Kim KI
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Chung, Woo-Young
AU  - Chung WY
AD  - Seoul National University Boramae Hospital, Seoul, South Korea.
FAU - Youn, Tae-Jin
AU  - Youn TJ
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Chae, In-Ho
AU  - Chae IH
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Choi, Dong-Ju
AU  - Choi DJ
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20130606
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Acute Coronary Syndrome/blood/*drug therapy/physiopathology
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/adverse effects
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Coronary Circulation/drug effects
MH  - Female
MH  - Hemorrhage/etiology
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/physiopathology/therapy
MH  - Partial Thromboplastin Time
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Risk Factors
MH  - Thrombolytic Therapy
OTO - NOTNLM
OT  - acute coronary syndromes
OT  - anticoagulants
OT  - bleeding
OT  - heparins
EDAT- 2013/06/08 06:00
MHDA- 2015/07/25 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/06/08 06:00 [entrez]
PHST- 2013/06/08 06:00 [pubmed]
PHST- 2015/07/25 06:00 [medline]
AID - 1076029613490826 [pii]
AID - 10.1177/1076029613490826 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2015 Jan;21(1):48-57. doi: 10.1177/1076029613490826. 
      Epub 2013 Jun 6.